Intercept Offloads Ex-US Business To Advanz, May Be Doubling Down On NASH In US
Executive Summary
Still working to refile its NASH fibrosis NDA 22 months after an FDA complete response letter, Intercept gets $405m up front for its ex-US business, including commercial rights to Ocaliva in PBC.